27550 Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis (AD) after treatment discontinuation in a phase 2b trial
2021
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI